Nutlin-3a

Catalog No.S8059 Synonyms: (-)-Nutlin-3

Nutlin-3a Chemical Structure

Molecular Weight(MW): 581.49

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

Size Price Stock Quantity  
USD 197 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 36 Publications

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.
Targets
p53/MDM2 interaction [3]
(Cell-free assay)
90 nM
In vitro

Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 M{DNTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXKe5ZbUUN3ME2wMlYyOjN5IN88US=> NVK1c5gyW0GQR1XS
H4 M3;tZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jYN2lEPTB;MD62OlI5KM7:TR?= NXzKWpZyW0GQR1XS
PA-1 NVvDNYtXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;UTWM2OD1yLki3NFk3KM7:TR?= NEPse29USU6JRWK=
NKM-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGn0c5pKSzVyPUGuNFQ6OzFizszN NW\hd2VnW0GQR1XS
NEC8 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXQTWM2OD1zLkKxOVczKM7:TR?= NH;KSZpUSU6JRWK=
EoL-1-cell MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn63TWM2OD1zLkK2O|AyKM7:TR?= MYrTRW5ITVJ?
K5 NXi5WXF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1T1NGlEPTB;MT60NlA4OiEQvF2= NGnoPHJUSU6JRWK=
QIMR-WIL NWfSS2R1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTEZppkUUN3ME2xMlYxQDV2IN88US=> MmnqV2FPT0WU
MOLT-16 NYfyTYd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPmTWM2OD1zLke4OlA1KM7:TR?= M1LpSHNCVkeHUh?=
CHP-212 MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnv2TWM2OD1zLkixN|Y6KM7:TR?= MmfyV2FPT0WU
CTB-1 Ml3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{j0NGlEPTB;Mj6wNlI1PiEQvF2= MYHTRW5ITVJ?
MOLT-4 MlXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJwM{K4OVMh|ryP NELBVYNUSU6JRWK=
A101D M2iy[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEiwNVZKSzVyPUKuN|UxOSEQvF2= NGK4ZWxUSU6JRWK=
DOHH-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTJwNEKyO|kh|ryP NWHFRWU2W0GQR1XS
ES4 MoPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnSTWM2OD1{LkSzNVU2KM7:TR?= NFvS[nFUSU6JRWK=
SW780 M2jlR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzmOFVKSzVyPUKuOVA5QDNizszN NXXUR5d7W0GQR1XS
VA-ES-BJ MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjqTWM2OD1{LkW0NVEh|ryP M4O0UnNCVkeHUh?=
RPMI-8866 M3rGWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTJwNU[yNVQh|ryP NWPLblc3W0GQR1XS
ML-2 MlLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1H2TGlEPTB;Mj61OlU4PiEQvF2= M1PLeHNCVkeHUh?=
MSTO-211H M2rOZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XZeWlEPTB;Mj61O|Q2OSEQvF2= NEnKZoNUSU6JRWK=
JVM-3 NVPMNWQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHtRYZKSzVyPUKuOVk{OjRizszN NFXEdIhUSU6JRWK=
A3-KAW M4H2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTJwNkG4NVgh|ryP NVHlXFFiW0GQR1XS
DK-MG NU\3cmU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXXVYlKSzVyPUKuOlI1PzFizszN M{TIeXNCVkeHUh?=
LNCaP-Clone-FGC MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[3bolKSzVyPUKuOlQ{OThizszN NGOyUlRUSU6JRWK=
HT-144 MlXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTJwNkS1O|ch|ryP NIr1cnpUSU6JRWK=
NB69 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTJwNkWzN|Qh|ryP NUDRTppQW0GQR1XS
A172 M1jkVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXoOWxKSzVyPUKuOlc2QDhizszN NFjYNItUSU6JRWK=
RS4-11 MnqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TZfmlEPTB;Mj63NlQxPyEQvF2= NXz2b3dTW0GQR1XS
DU-4475 MlXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULQVlNIUUN3ME2yMlc6PTB{IN88US=> NHjDZXVUSU6JRWK=
SJSA-1 NYjyRXN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPmTWM2OD1{LkiyOVU3KM7:TR?= NV7wOVZqW0GQR1XS
BV-173 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vsTWlEPTB;Mj64OFQ{QSEQvF2= NEKxNWRUSU6JRWK=
U-2-OS NIH1e3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nKN2lEPTB;Mj65NVA4KM7:TR?= NHjzNpBUSU6JRWK=
CHP-134 NU\EboFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfrcWJKSzVyPUKuPVM5QDJizszN MojsV2FPT0WU
D-502MG MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mof6TWM2OD1{Lkm3NVU1KM7:TR?= NV;ITGZSW0GQR1XS
KS-1 NXLOT5Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofnTWM2OD1|LkCxOlI{KM7:TR?= MXfTRW5ITVJ?
A204 NG\Lco5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXtZlNKSzVyPUOuNFU2QDhizszN NEjSVXpUSU6JRWK=
KGN NF7lOnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjRWYRKSzVyPUOuNFg1QTZizszN NXTjbHBxW0GQR1XS
NCI-H292 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTNwMUKwNlgh|ryP MojqV2FPT0WU
CAKI-1 NUnQeWQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTNwMUK2PVQh|ryP M2jI[HNCVkeHUh?=
C2BBe1 Mn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\We2lKSzVyPUOuNVcxOjZizszN MVrTRW5ITVJ?
NB10 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17UdWlEPTB;Mz6yNFk3PiEQvF2= NYHIVIJXW0GQR1XS
MHH-NB-11 NWfRNGFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPi[Yt7UUN3ME2zMlI3QDJ5IN88US=> NH:yVXFUSU6JRWK=
NCI-SNU-1 NV;3T5BmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnS1TWM2OD1|LkK3PFQ{KM7:TR?= NUT1e|BSW0GQR1XS
HCT-116 NYPIe2dpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;JW2lEPTB;Mz6zNFM{PSEQvF2= M{\XUXNCVkeHUh?=
G-401 Ml\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHyToZKSzVyPUOuN|Y{OjJizszN M1\zfHNCVkeHUh?=
MN-60 NEL4NJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTNwNESwPVIh|ryP Mn21V2FPT0WU
SW982 Ml7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf3fXlKSzVyPUOuOVA5PDhizszN MlfoV2FPT0WU
RKO MmC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDYRnlKSzVyPUOuOVM6OzZizszN MWnTRW5ITVJ?
D-283MED MomwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XPZ2lEPTB;Mz61O|k5PiEQvF2= MnnPV2FPT0WU
LB996-RCC NFHvTmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkmwTWM2OD1|Lk[yOVU5KM7:TR?= M1PyXHNCVkeHUh?=
A549 MoftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XuOWlEPTB;Mz62N|U2OiEQvF2= M1\4ZXNCVkeHUh?=
LB2241-RCC MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LieGlEPTB;Mz62OVcxQCEQvF2= MlTyV2FPT0WU
SK-HEP-1 NVPqPIVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTk[ZNKSzVyPUOuO|QzQTdizszN NITQfXdUSU6JRWK=
G-402 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHrPINiUUN3ME2zMlgxQDN{IN88US=> NVW5WIRLW0GQR1XS
GOTO MlfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnROYFyUUN3ME2zMlg1OzN|IN88US=> NInObmlUSU6JRWK=
LOXIMVI NXfFPVl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTNwOEW2O|Uh|ryP NV\GcotXW0GQR1XS
NH-12 MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTRwMEG5OVkh|ryP NXLwZXg6W0GQR1XS
CTV-1 NEDYdmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrqeWxoUUN3ME20MlA4QTd|IN88US=> MkPRV2FPT0WU
CP50-MEL-B NHzxSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHrV2hrUUN3ME20MlI1Ozl{IN88US=> M374UnNCVkeHUh?=
RH-18 NI\sbJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7aS3NpUUN3ME20MlI4PzB4IN88US=> M{X6bHNCVkeHUh?=
NB17 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTlSW5zUUN3ME20MlMyPzZ6IN88US=> MmrZV2FPT0WU
A375 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPMTWM2OD12LkOzOVI1KM7:TR?= NGrGXWRUSU6JRWK=
IST-MES1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXMSHoyUUN3ME20MlQyPDFzIN88US=> MlrUV2FPT0WU
MZ2-MEL NIfCWWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7ZU2pKSzVyPUSuOVAyPTVizszN MVLTRW5ITVJ?
CAL-54 M3rJemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTRwNUOwNVkh|ryP NYrm[YVmW0GQR1XS
NCI-H28 NXj3c5lWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorKTWM2OD12Lk[yO|E4KM7:TR?= NWnRZ4RqW0GQR1XS
D-247MG MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHn0W5ZKSzVyPUSuO|UxPzJizszN NFXEU4FUSU6JRWK=
NCI-H460 NHezXWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTRwOUGxNlch|ryP NV7XZXpoW0GQR1XS
MCF7 NIPJeGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPZNldKSzVyPUWuOFQzPDRizszN MoDlV2FPT0WU
697 NW\QUphET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTVwNES1OUDPxE1? NHezd2lUSU6JRWK=
ONS-76 NIn6cIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEWw[nJKSzVyPUWuOVcxODlizszN Ml7GV2FPT0WU
C32 MmnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorVTWM2OD13Lk[wNFI6KM7:TR?= NFfXeVlUSU6JRWK=
OS-RC-2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HzNWlEPTB;NT63N|g5PyEQvF2= M1XHV3NCVkeHUh?=
MEL-HO MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDRb29KSzVyPUWuPFU3PjdizszN MUfTRW5ITVJ?
LoVo M1Pvb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnKdndvUUN3ME22MlAyPjJ2IN88US=> MXvTRW5ITVJ?
AGS M3PnWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTMeZFKSzVyPU[uNVQ5OjhizszN MYnTRW5ITVJ?
GI-ME-N Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvkcYZKSzVyPU[uNlI1OjFizszN Ml:4V2FPT0WU
H-EMC-SS M4rPZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvOTWM2OD14LkO4OkDPxE1? MoO0V2FPT0WU
RVH-421 M3vkcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUSxbHg4UUN3ME22MlQzPDJ6IN88US=> NW\XWo5VW0GQR1XS
SW954 NEHEWGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGj3SFlKSzVyPU[uOVU2PzJizszN NH:5cFZUSU6JRWK=
NB5 NF3LSVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{G3[WlEPTB;Nj61OlE5OyEQvF2= NFjVZ|FUSU6JRWK=
NCI-H2122 NUj0T3hnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrQWJNPUUN3ME22MlU5Pzl|IN88US=> MXzTRW5ITVJ?
AM-38 NHW2cmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3WNFU2UUN3ME22Mlc2PjN7IN88US=> MmTwV2FPT0WU
KNS-81-FD MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrlPWJKSzVyPU[uO|Y1QTRizszN MYXTRW5ITVJ?
LS-513 NEDqRYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTZwN{mwNlYh|ryP MVjTRW5ITVJ?
A427 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTZwOEe4Nlkh|ryP MVrTRW5ITVJ?
WM-115 M3X3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXNTWM2OD14LkmzNlMh|ryP NIraUodUSU6JRWK=
COLO-829 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnDZVNRUUN3ME23MlI1OTh6IN88US=> NUHGUHJTW0GQR1XS
NCI-H1650 Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTdwM{myNlgh|ryP M3O0OXNCVkeHUh?=
NCI-H358 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz2d4dKSzVyPUeuOFQ5PzlizszN MXvTRW5ITVJ?
HT-1080 NG\XS4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTdwNEiyOVQh|ryP NXvab2xlW0GQR1XS
HCC2218 NX:xVZZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnQTWM2OD15Lk[yPVch|ryP MUTTRW5ITVJ?
NCI-H661 NFzJXphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33P[2lEPTB;Nz64O|A3QSEQvF2= MnjjV2FPT0WU
KM-H2 M1vGUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnZNGZUUUN3ME23Mlg5Pjl2IN88US=> NIDvfmpUSU6JRWK=
RPMI-2650 NXrKe5NbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFr2XHdKSzVyPUeuPVQ1OTRizszN M{TsPHNCVkeHUh?=
NCI-H226 M3vrWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2W3bGlEPTB;OD6yNVEzOiEQvF2= M2exN3NCVkeHUh?=
MKN45 M4XuRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LWXmlEPTB;OD6yOlYxOiEQvF2= NFf4dGxUSU6JRWK=
D-392MG NWfwPHBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljUTWM2OD16LkWyO|IzKM7:TR?= MWfTRW5ITVJ?
RCC10RGB NFXTUHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRThwOE[2PVUh|ryP MlrFV2FPT0WU
CAL-51 NWjCb286T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTlwMUCyOVEh|ryP M2K1NnNCVkeHUh?=
COLO-678 NV3jVpJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3joUGlEPTB;OT6zNlgyOSEQvF2= NH7DbZZUSU6JRWK=
SK-MEL-24 M1nwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnGTWM2OD17LkW1PFU3KM7:TR?= MVjTRW5ITVJ?
SK-MEL-30 NGLjfFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGS5V5JKSzVyPUmuPVQ1PzZizszN NFPz[W1USU6JRWK=
MMAC-SF NGPDXI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIj3[5RKSzVyPUGwMlM6PjFizszN M4fCOnNCVkeHUh?=
NTERA-S-cl-D1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTFyLk[1NFgh|ryP M2O0dnNCVkeHUh?=
NB12 MnXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPRTHdRUUN3ME2xNU42ODNizszN M3G2TXNCVkeHUh?=
UACC-257 NEP1OIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPsUnJmUUN3ME2xNU45Pjl3IN88US=> MnK3V2FPT0WU
LAN-6 NVzxeIxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\nVZdKSzVyPUGxMlk6OjhizszN MkHwV2FPT0WU
SW1573 MkTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXq4[VA6UUN3ME2xNk4{ODh4IN88US=> MoTRV2FPT0WU
NMC-G1 MoK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTF{LkSxO|Uh|ryP Mn\5V2FPT0WU
SHP-77 NX3rSlhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrVTWM2OD1zMj61OVc1KM7:TR?= MX\TRW5ITVJ?
IGROV-1 M2LCbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlKwTWM2OD1zMj62OVc{KM7:TR?= M3zOXnNCVkeHUh?=
22RV1 NIXvfJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rEeWlEPTB;MUKuPFA2QSEQvF2= MXTTRW5ITVJ?
SK-MEL-3 NVn4XIVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTF|LkO5O|Mh|ryP NILkd3lUSU6JRWK=
NCI-H1563 Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTkTWM2OD1zMz60NlAzKM7:TR?= MlO5V2FPT0WU
IGR-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2KwSmlEPTB;MUSuNFM1PyEQvF2= NU\Me3ljW0GQR1XS
EW-3 M{nqPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLrTWM2OD1zND6xOlM6KM7:TR?= M13qUnNCVkeHUh?=
JEG-3 MojzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M175RmlEPTB;MUSuOFk2OyEQvF2= NWjMRnk1W0GQR1XS
ES3 NWLCS21GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLDXHZKSzVyPUG0MlY2PjJizszN MnzSV2FPT0WU
MDA-MB-175-VII MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTF2LkexNVEh|ryP MVfTRW5ITVJ?
P30-OHK Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTF3LkC0PVYh|ryP MUTTRW5ITVJ?
GP5d MnTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLLTZJKSzVyPUG1MlE1PjZizszN M176OnNCVkeHUh?=
HMV-II NVHMe|N2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTF3LkOzN|Mh|ryP MoLJV2FPT0WU
COLO-679 MmnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LsWWlEPTB;MUWuOVAyKM7:TR?= NWHDO2x[W0GQR1XS
JAR NUfQXGVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPoTWM2OD1zNT63NlA2KM7:TR?= MnviV2FPT0WU
NCI-H1666 M{XOSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnu4TWM2OD1zNT65N|k6KM7:TR?= NEjybZFUSU6JRWK=
SW48 NH[xdFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfmcWNrUUN3ME2xOU46PTF4IN88US=> M{XCbXNCVkeHUh?=
NCI-H720 M4HQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTF3Lkm5PFkh|ryP M3juNXNCVkeHUh?=
HT-1197 NXnX[XUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;PTWM2OD1zNj6wN|UzKM7:TR?= Mn\CV2FPT0WU
HL-60 NEf5UWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTF4LkCzPFQh|ryP NWrmR3ZGW0GQR1XS
BEN Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXQTWM2OD1zNj61OlM5KM7:TR?= NXm0[oYyW0GQR1XS
HAL-01 NHu3VWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[5PJhKSzVyPUG2Mlg6ODlizszN NXfWRpM6W0GQR1XS
SW900 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzETWM2OD1zNj65NVMzKM7:TR?= M3H0VHNCVkeHUh?=
SBC-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnxZlJKSzVyPUG3MlU1OjlizszN MmL3V2FPT0WU
SH-4 M1TRb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPJRoM3UUN3ME2xO{42QDRzIN88US=> Mk\5V2FPT0WU
UACC-62 MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF5Lke2N|ch|ryP M3;aVXNCVkeHUh?=
BHT-101 NEL1bpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYq4OmN4UUN3ME2xPU45PzB3IN88US=> MVvTRW5ITVJ?
DB MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TQdWlEPTB;MkGuOVY1QSEQvF2= M1W4fXNCVkeHUh?=
SK-MEL-1 NFLPU21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITyVYlKSzVyPUKxMlU5PzJizszN MnrsV2FPT0WU
NCI-H747 NY[4RlF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXaTWM2OD1{Mj63N|c6KM7:TR?= MV7TRW5ITVJ?
SK-LU-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDrS|FKSzVyPUKzMlM2OjRizszN NX\5RpcxW0GQR1XS
KG-1 NFnGS2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJ|LkS5OFYh|ryP Mmn1V2FPT0WU
LXF-289 Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX63eYtSUUN3ME2yN{44OTRizszN MV3TRW5ITVJ?
HCC1954 M{[1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHuweJFKSzVyPUK0Mlg5PDRizszN NUjrVpN{W0GQR1XS
Ramos-2G6-4C10 NU\hT4hjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzpTWM2OD1{Nj60PVgyKM7:TR?= NGL5bmRUSU6JRWK=
DBTRG-05MG MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDHTWM2OD1{Nj62OFg5KM7:TR?= Ml;XV2FPT0WU
NCI-H2052 M3fJdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2iyb2lEPTB;MkeuOVY5PCEQvF2= NWDRT5JRW0GQR1XS
RMG-I NG\KdItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Pad2lEPTB;MkmuOFE{QSEQvF2= MVTTRW5ITVJ?
H9 MkC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2exRmlEPTB;M{GuN|AxQCEQvF2= NYfqNlZiW0GQR1XS
GR-ST MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnDTWM2OD1|Mj60OFU{KM7:TR?= M2fSSXNCVkeHUh?=
Mo-T MlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XtNGlEPTB;M{KuOVA1PiEQvF2= MmK3V2FPT0WU
SW1088 M{XMXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnSSItzUUN3ME2zNk46QDBzIN88US=> MUTTRW5ITVJ?
LB2518-MEL MlzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTN|LkC3PVch|ryP MoWwV2FPT0WU
NCI-H82 MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTN|LkG2OlEh|ryP MofMV2FPT0WU
LAMA-84 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkT2TWM2OD1|ND62NFc{KM7:TR?= M4rLSHNCVkeHUh?=
KYSE-450 NUfyUGRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLtUnF3UUN3ME2zOE43Pzd4IN88US=> MofTV2FPT0WU
LU-99A M3Xqc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHifoVKSzVyPUO1MlAxODdizszN MnvhV2FPT0WU
BE-13 MlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTIN3B7UUN3ME2zOU43PTR3IN88US=> MkXjV2FPT0WU
GAK NVLFZY1HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DhNGlEPTB;M{WuOlk2KM7:TR?= Mn70V2FPT0WU
NCI-H1573 M1HpN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTKV4JmUUN3ME2zOU45QDF6IN88US=> MUfTRW5ITVJ?
AsPC-1 NH;BbpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfjdHhIUUN3ME2zOk4yPTJ5IN88US=> MXzTRW5ITVJ?
HDLM-2 NGXjb5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTN4LkOxOkDPxE1? MXXTRW5ITVJ?
NCI-H441 NED2botIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTN5LkC2PVEh|ryP MkW1V2FPT0WU
CAL-27 M320fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTN5LkeyN|Eh|ryP MnrOV2FPT0WU
OVCAR-3 NXfMXWJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTOTWM2OD1|OT6zNVgyKM7:TR?= MV3TRW5ITVJ?
RPMI-8226 NYnJNY9IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XmWGlEPTB;M{muOVk5KM7:TR?= NHzL[HNUSU6JRWK=
EFO-21 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTRyLkW4NVQh|ryP MlvGV2FPT0WU
SNU-C2B MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGq5PIFKSzVyPUSxMlUxQDRizszN MV3TRW5ITVJ?
VM-CUB-1 MlHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlyzTWM2OD12Mz64NFM4KM7:TR?= M3rHWHNCVkeHUh?=
NCI-H2087 NUPOZmZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXvWW1nUUN3ME20OU4xOjN|IN88US=> NGDqSJJUSU6JRWK=
EW-16 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHS3R2xKSzVyPUS2MlMyOzdizszN NUf5UnpWW0GQR1XS
SK-N-AS NX7GR3k4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PnN2lEPTB;NE[uO|E3PyEQvF2= NUjQOXlJW0GQR1XS
COR-L105 NEfhOpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHpTWM2OD12Nj64PFU4KM7:TR?= NX\ZS3NzW0GQR1XS
DEL MofiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfpdoJYUUN3ME20PE4xPDJ7IN88US=> NF7yblhUSU6JRWK=
JVM-2 M1jUfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTR6LkC1OVgh|ryP MUTTRW5ITVJ?
KARPAS-45 MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrOc4lKSzVyPUS5MlQ2OzhizszN NH[xTohUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / MDM2 / p21 / Bax / Bak / Noxa / cleaved caspase / pro-caspase; 

PubMed: 16014563     


Expression of apoptosis- and cell-cycle–associated proteins in OCI-AML-3 cells, which were treated with 5 μM Nutlin-3a for the indicated times. Nutlin-3a induced increased protein expression of p53, MDM2, and p21 in OCI-AML-3 cells in a time-dependent fashion. Nutlin-3a induced Noxa, a BH3-only member of the Bcl-2 family, followed by caspase activation. β-actin was used to confirm equal loading of proteins. Arrowheads indicate cleared caspases.

BMI-1; 

PubMed: 26887044     


Western blot analysis of BMI-1 and actin was performed in BV-173, SUP-B15, NALM-6, NALM-19 and REH cell lines after 24 hours treatment with increasing concentrations of Nutlin-3a (1 μM, 2 μM, 5 μM) and with DMSO control. 

p53-Ser15 / p53-Ser37 / p53-Lys382 / MDM2 / CDC2 / PLK1 / HSC70; 

PubMed: 23666059     


Expression of the indicated proteins in whole-cell lysates of cells treated for 96 h with 50 μM resveratrol (R), 5 μM nutlin-3a (N), or co-treated with both substances (RN).

16014563 26887044 23666059
Immunofluorescence
p-p21 / β-actin; 

PubMed: 31083332     


Cells were treated with fluoride (5 mM) with/without Nutlin-3a for 24 h. p-p21 (green), nucleus (DAPI; blue) and β-actin (red) expression were detected by immunocytochemistry. Nutlin-3a addition augmented p-p21 expression compared to NaF treatment alone.

P53; 

PubMed: 21394100     


At 12 h following treatment with nutlin-3a, DoHH2 and MCA cells had increased levels of p53 visualized by immunofluorescence. p53 localization was predominantly nuclear. The 4',6-diamidino-2-phenylindole was used as counterstain of the nuclei.

Ac-p300; 

PubMed: 30240745     


HepG2 cells were treated with 5 μM Nutlin-3a for 24 hr, and the levels of Ac-p300 and p53 were assessed by co-immunofluorescence. Fluorescence intensity of Ac-p300 in control cells versus Nutlin-3a-treated cells have been quantified (represented as mean ± SD, unpaired two-tailed Student's t test, n = 50 of three independent experiments). Scale bar, 10 μm.

31083332 21394100 30240745
Growth inhibition assay
Cell viability; 

PubMed: 26248031     


All 15 cell lines were plated in 96-well plates. After 24h, media was exchanged and cells were treated with incremental concentrations of Nutlin-3a (1 μM, 5 μM, 10 μM, 25 μM, 50 μM, and 70 μM). After 72h of Nutlin-3a treatment, cell viability was measured by WST assay and compared to untreated control.

26248031
In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.

Protocol

Kinase Assay:[3]
- Collapse

Biacore studies:

Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel
Cell Research:[2]
- Collapse
  • Cell lines: OSA, T778, RMS13, U2OS, SaOS-2
  • Concentrations: ~5 μM
  • Incubation Time: 120 h
  • Method: SRB
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: SJSA-1 xenograft
  • Formulation: 1% Klucel, 0.1% Tween 80
  • Dosages: 50, 100, 200 mg/kg twice daily
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+55% PEG 300+ddH2O
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage powder
in solvent
Synonyms (-)-Nutlin-3

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between S1061 (Nutlin-3) and S8059 (Nutlin-3a)?

  • Answer:

    S1061 is a racemic mixture of Nutlin3a and Nutlin3b. s8059 is the active enantiomer of Nutlin3.

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID